Strepsils Extra Triple Action Cherry 2.4mg lozenges

Pajjiż: Ingilterra

Lingwa: Ingliż

Sors: MHRA (Medicines & Healthcare Products Regulatory Agency)

Ingredjent attiv:

Hexylresorcinol

Disponibbli minn:

Reckitt Benckiser Healthcare (UK) Ltd

Kodiċi ATC:

R02AA12

INN (Isem Internazzjonali):

Hexylresorcinol

Dożaġġ:

2.4mg

Għamla farmaċewtika:

Lozenge

Rotta amministrattiva:

Oromucosal

Klassi:

No Controlled Drug Status

Tip ta 'preskrizzjoni:

Valid as a prescribable product

Sommarju tal-prodott:

BNF: 12030300; GTIN: 5000158106208

Karatteristiċi tal-prodott

OBJECT 1
STREPSILS EXTRA TRIPLE ACTION CHERRY LOZENGES
Summary of Product Characteristics Updated 16-Jul-2015 | Reckitt
Benckiser Healthcare (UK) Ltd
1. Name of the medicinal product
Strepsils Extra Cherry Lozenges
Strepsils Extra Triple Action Cherry Lozenges
Strepsils Extra Strength Cherry Lozenges
2. Qualitative and quantitative composition
Each lozenge contains Hexylresorcinol 2.4mg
For excipients see Section 6.1
3. Pharmaceutical form
Lozenge
A round red lozenge with the Strepsils brand icon entagliated on both
sides.
4. Clinical particulars
4.1 Therapeutic indications
As an antiseptic and local anaesthetic for the relief of sore throat
and its associated pain
4.2 Posology and method of administration
For oral administration.
Adults, the elderly and children 6 years and over: One lozenge
dissolved slowly in the mouth every three
hours or as required.
Do not take more than 12 lozenges in 24 hours.
Not to be given to children under 6 years.
4.3 Contraindications
Hypersensitivity to any of the ingredients
4.4 Special warnings and precautions for use
The label will convey:
Keep out of the reach and sight of children.
If symptoms persist consult your doctor.
Not to be given to children under 6 years.
This product is unsuitable in hereditary fructose intolerance,
glucose-galactose malabsorption syndrome,
or sucrose-isomaltase deficiency.
4.5 Interaction with other medicinal products and other forms of
interaction
None known
4.6 Pregnancy and lactation
There is lack of evidence of safety of the product in human pregnancy
and in animals, but hexylresorcinol
has been used widely in lozenges for many years without apparent ill
consequence. However, as with all
medicines, caution should be exercised during pregnancy and lactation.
4.7 Effects on ability to drive and use machines
None known
4.8 Undesirable effects
None known
4.9 Overdose
Hexylresorcinol overdosage may cause minor gastrointestinal
irritation. Treatment would be withdrawal
of the product and symptomatic measures as appropriate.
5. Pharmacological properti